
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions β written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Myelofibrosis causes
Introduction
Overview
Overview
Myelofibrosis is most commonly caused by somatic mutations in the myeloproliferative leukemia virus (MPL) oncogene, the calreticulin (CALR) gene, or Janus kinase 2 (JAK2) gene. Less common mutations in other genes have also been documented. It can also be the result of other primary disorders manifesting as a complication or part of the disease process. Infections, malignancies, hematologic disorders, autoimmune diseases and exposure to certain toxins can also cause myelofibrosis.
Causes
Causes
Life-threatening Causes
There are no life-threatening causes of myelofibrosis, however complications resulting from untreated myelofibrosis is common.
Common Causes
Common causes of myelofibrosis include:
- Genetic mutations in:
Less Common Causes
- Infection[22][23][24][25]
- Autoimmunity[26][27][28][29]
- Toxins exposure[30][31][32][33][34][35][36][37]
- Primary hyperparathyroidism[38]
Genetic Causes
Common
Myelofibrosis is commonly caused by mutations in the following genes:
- Myeloproliferative leukemia virus (MPL) oncogene[1][2][3][4][5][6][7][8][9][10][11]
- Calreticulin (CALR) gene[1][2][3][4][5][6][7][8]
- Janus kinase 2 (JAK2) gene[9][10][11]
Less Common
Myelofibrosis is less-commonly caused by mutations in the following genes:
- Additional sex combs-like 1 (ASXL1)[39]
- Slicing factor, serine/arginine-rich 2 (SRSF2)[39]
- Enhancer of zeste, drosophila, homolog 2 (EZH2)[39]
- Neuroblastoma RAS viral oncogene homolog (NRAS)[39]
- Kirsten rat sarcoma viral oncogene homolog (KRAS)[39]
- Protein-tyrosine phosphatase, non-receptor type 11 (PTPN11)[39]
- GATA-binding protein 2 (GATA2)[39]
- Tumor protein p53 (TP53)[39]
- Runt-related transcription factor 1 (RUNX1)[39]
Causes by Organ System
| Cardiovascular | No underlying causes |
| Chemical/Poisoning | benzene, thorium dioxide, nitrosurea[30][31][32][33][34][35][36][37] |
| Dental | No underlying causes |
| Dermatologic | No underlying causes |
| Drug Side Effect | No underlying causes |
| Ear Nose Throat | No underlying causes |
| Endocrine | Primary hyperparathyroidism[38] |
| Environmental | benzene, nitrosurea[30][31][32][33][34] |
| Gastroenterologic | No underlying causes |
| Genetic | Mutations in multiple genes discussed above |
| Hematologic | Essential thrombocythemia (ET), Polycythemia vera (PV), and Multiple myeloma (MM)[16][17][18][19][20][21] |
| Iatrogenic | No underlying causes |
| Infectious Disease | tuberculosis (TB), HIV infection, and dengue fever[22][23][24][25] |
| Musculoskeletal/Orthopedic | No underlying causes |
| Neurologic | No underlying causes |
| Nutritional/Metabolic | No underlying causes |
| Obstetric/Gynecologic | No underlying causes |
| Oncologic | Hodgkin’s lymphoma, Non-Hodgkin lymphoma, and Bone metastases[12][13][14][15][40] |
| Ophthalmologic | No underlying causes |
| Overdose/Toxicity | No underlying causes |
| Psychiatric | No underlying causes |
| Pulmonary | No underlying causes |
| Renal/Electrolyte | No underlying causes |
| Rheumatology/Immunology/Allergy | No underlying causes |
| Sexual | No underlying causes |
| Trauma | No underlying causes |
| Urologic | No underlying causes |
| Miscellaneous | x- or Ξ³-radiation exposure |
References
References
- β 1.0 1.1 1.2 1.3 Tefferi A (December 2016). “Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management”. Am. J. Hematol. 91 (12): 1262β1271. doi:10.1002/ajh.24592. PMIDΒ 27870387.
- β 2.0 2.1 2.2 2.3 Tefferi, A; Lasho, T L; Finke, C M; Knudson, R A; Ketterling, R; Hanson, C H; Maffioli, M; Caramazza, D; Passamonti, F; Pardanani, A (2014). “CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons”. Leukemia. 28 (7): 1472β1477. doi:10.1038/leu.2014.3. ISSNΒ 0887-6924.
- β 3.0 3.1 3.2 3.3 Baxter EJ, Scott LM, Campbell PJ; et al. (2005). “Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders”. Lancet. 365 (9464): 1054β61. doi:10.1016/S0140-6736(05)71142-9. PMIDΒ 15781101.
- β 4.0 4.1 4.2 4.3 Pikman Y, Lee BH, Mercher T; et al. (2006). “MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia”. PLoS Med. 3 (7): e270. doi:10.1371/journal.pmed.0030270. PMCΒ 1502153. PMIDΒ 16834459. Unknown parameter
|month=ignored (help) - β 5.0 5.1 5.2 5.3 Alshemmari SH, Rajan R, Emadi A (2016). “Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review”. Med Princ Pract. 25 (6): 501β509. doi:10.1159/000450956. PMCΒ 5588514. PMIDΒ 27756071.
- β 6.0 6.1 6.2 6.3 Shammo JM, Stein BL (December 2016). “Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions”. Hematology Am Soc Hematol Educ Program. 2016 (1): 552β560. doi:10.1182/asheducation-2016.1.552. PMCΒ 6142495. PMIDΒ 27913528.
- β 7.0 7.1 7.2 7.3 Li B, Xu J, Wang J, Gale RP, Xu Z, Cui Y, Yang L, Xing R, Ai X, Qin T, Zhang Y, Zhang P, Xiao Z (November 2014). “Calreticulin mutations in Chinese with primary myelofibrosis”. Haematologica. 99 (11): 1697β700. doi:10.3324/haematol.2014.109249. PMCΒ 4222480. PMIDΒ 24997152.
- β 8.0 8.1 8.2 8.3 Rotunno G, Pacilli A, Artusi V, Rumi E, Maffioli M, Delaini F, Brogi G, Fanelli T, Pancrazzi A, Pietra D, Bernardis I, Belotti C, Pieri L, Sant’Antonio E, Salmoiraghi S, Cilloni D, Rambaldi A, Passamonti F, Barbui T, Manfredini R, Cazzola M, Tagliafico E, Vannucchi AM, Guglielmelli P (July 2016). “Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group”. Am. J. Hematol. 91 (7): 681β6. doi:10.1002/ajh.24377. PMIDΒ 27037840.
- β 9.0 9.1 9.2 9.3 Song J, Hussaini M, Zhang H, Shao H, Qin D, Zhang X, Ma Z, Hussnain Naqvi SM, Zhang L, Moscinski LC (May 2017). “Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis”. Am. J. Clin. Pathol. 147 (5): 444β452. doi:10.1093/ajcp/aqw222. PMCΒ 5402718. PMIDΒ 28419183.
- β 10.0 10.1 10.2 10.3 Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, Finke C, Score J, Gangat N, Mannarelli C, Ketterling RP, Rotunno G, Knudson RA, Susini MC, Laborde RR, Spolverini A, Pancrazzi A, Pieri L, Manfredini R, Tagliafico E, Zini R, Jones A, Zoi K, Reiter A, Duncombe A, Pietra D, Rumi E, Cervantes F, Barosi G, Cazzola M, Cross NC, Tefferi A (September 2013). “Mutations and prognosis in primary myelofibrosis”. Leukemia. 27 (9): 1861β9. doi:10.1038/leu.2013.119. PMIDΒ 23619563.
- β 11.0 11.1 11.2 11.3 Tefferi A, Pardanani A (April 2015). “Myeloproliferative Neoplasms: A Contemporary Review”. JAMA Oncol. 1 (1): 97β105. doi:10.1001/jamaoncol.2015.89. PMIDΒ 26182311.
- β 12.0 12.1 Boiocchi L, Mathew S, Gianelli U, Iurlo A, Radice T, Barouk-Fox S, Knowles DM, Orazi A (December 2013). “Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage”. Mod. Pathol. 26 (12): 1577β85. doi:10.1038/modpathol.2013.109. PMIDΒ 23787440.
- β 13.0 13.1 Sakatoku K, Takeoka Y, Araki T, Miura A, Fujitani Y, Yamamura R, Miyagi Y, Senzaki H, Ohta K (2017). “Lymphocyte-depleted classical Hodgkin lymphoma accompanied by myelofibrosis”. Rinsho Ketsueki (in Japanese). 58 (7): 772β775. doi:10.11406/rinketsu.58.772. PMIDΒ 28781273.
- β 14.0 14.1 Fu R, Yu H, Wu YH, Liu H, Shao ZH (September 2015). “Hodgkin’s lymphoma associated with myelofibrosis: A case report”. Oncol Lett. 10 (3): 1551β1554. doi:10.3892/ol.2015.3438. PMCΒ 4533276. PMIDΒ 26622707.
- β 15.0 15.1 Liu YL, Wang WJ, Wang XN (June 2015). “[Pathological Characteristics of Bone Marrow in Non-Hodgkin’s Lymphoma Patients with Secondary Myelofibrosis and Their Relationship with Prognosis]”. Zhongguo Shi Yan Xue Ye Xue Za Zhi (in Chinese). 23 (3): 674β8. doi:10.7534/j.issn.1009-2137.2015.03.014. PMIDΒ 26117015.
- β 16.0 16.1 16.2 Dolgikh TY, Domnikova NP, Tornuev YV, Vinogradova EV, Krinitsyna YM (February 2017). “Incidence of Myelofibrosis in Chronic Myeloid Leukemia, Multiple Myeloma, and Chronic Lymphoid Leukemia during Various Phases of Diseases”. Bull. Exp. Biol. Med. 162 (4): 483β487. doi:10.1007/s10517-017-3645-x. PMIDΒ 28239786.
- β 17.0 17.1 Zhao J, Ma L, Guan JH (August 2017). “[Pathological Characteristics of Bone Marrow in Multiple Myeloma Patients with Secondary Myelofibrosis and Their Relationship with Prognosis]”. Zhongguo Shi Yan Xue Ye Xue Za Zhi (in Chinese). 25 (4): 1080β1085. doi:10.7534/j.issn.1009-2137.2017.04.021. PMIDΒ 28823272.
- β 18.0 18.1 Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM (December 2017). “A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis”. Leukemia. 31 (12): 2726β2731. doi:10.1038/leu.2017.169. PMIDΒ 28561069.
- β 19.0 19.1 Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek S (August 2017). “Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis”. Leuk. Res. 59: 110β116. doi:10.1016/j.leukres.2017.06.001. PMCΒ 5573611. PMIDΒ 28601551.
- β 20.0 20.1 MARKAND ON (May 1965). “SECONDARY MARBLE BONE DISEASE: GENERALISED OSTEOSCLEROSIS AND MYELOFIBROSIS IN CARCINOMA OF PROSTATE WITH A CASE REPORT”. J Assoc Physicians India. 13: 349β55. PMIDΒ 14302719.
- β 21.0 21.1 Chang JC, Naqvi T (2003). “Thrombotic thrombocytopenic purpura associated with bone marrow metastasis and secondary myelofibrosis in cancer”. Oncologist. 8 (4): 375β80. PMIDΒ 12897334.
- β 22.0 22.1 Qing X, Sun N, Yeh J, Yue C, Cai J (October 2014). “Dengue fever and bone marrow myelofibrosis”. Exp. Mol. Pathol. 97 (2): 208β10. doi:10.1016/j.yexmp.2014.07.004. PMIDΒ 25016180.
- β 23.0 23.1 Lee AC, Fong CM (May 2012). “Autoimmune myelofibrosis as the first manifestation of human immunodeficiency virus infection in an infant”. Ann. Hematol. 91 (5): 809β810. doi:10.1007/s00277-011-1329-6. PMIDΒ 21894472.
- β 24.0 24.1 Hashim MS, Kordofani AY, el Dabi MA (March 1997). “Tuberculosis and myelofibrosis in children: a report”. Ann Trop Paediatr. 17 (1): 61β5. PMIDΒ 9176580.
- β 25.0 25.1 Viallard JF, Parrens M, Boiron JM, Texier J, Mercie P, Pellegrin JL (June 2002). “Reversible myelofibrosis induced by tuberculosis”. Clin. Infect. Dis. 34 (12): 1641β3. doi:10.1086/340524. PMIDΒ 12032901.
- β Jain N, Sinha R, Sengupta J, Chakrabartty J (June 2016). “A rare case of myelofibrosis secondary to juvenile idiopathic arthritis”. Br. J. Haematol. 173 (6): 819. doi:10.1111/bjh.14106. PMIDΒ 27102067.
- β Cansu DΓ, Teke HΓ, Korkmaz C (March 2017). “A rare cause of cytopenia in a patient with systemic lupus erythematosus: Autoimmune myelofibrosis”. Eur J Rheumatol. 4 (1): 76β78. doi:10.5152/eurjrheum.2016.011. PMCΒ 5335895. PMIDΒ 28293461.
- β Thorsteinsdottir S, Bjerrum OW, Hasselbalch HC (2013). “Myeloproliferative neoplasms in five multiple sclerosis patients”. Leuk Res Rep. 2 (2): 61β3. doi:10.1016/j.lrr.2013.06.004. PMCΒ 3850374. PMIDΒ 24371783.
- β Abaza Y, Yin CC, Bueso-Ramos CE, Wang SA, Verstovsek S (April 2017). “Primary autoimmune myelofibrosis: a case report and review of the literature”. Int. J. Hematol. 105 (4): 536β539. doi:10.1007/s12185-016-2129-5. PMIDΒ 27830539.
- β 30.0 30.1 30.2 BausΓ R, Navarro L, CortΓ¨s-Franch I (2017). “[Myelofibrosis in a benzene-exposed cleaning worker]”. Arch Prev Riesgos Labor (in Spanish; Castilian). 20 (3): 167β169. doi:10.12961/aprl.2017.20.3.03. PMIDΒ 28715625.
- β 31.0 31.1 31.2 Hu H (January 1987). “Benzene-associated myelofibrosis”. Ann. Intern. Med. 106 (1): 171β2. PMIDΒ 3789571.
- β 32.0 32.1 32.2 Tondel M, Persson B, Carstensen J (February 1995). “Myelofibrosis and benzene exposure”. Occup Med (Lond). 45 (1): 51β2. PMIDΒ 7703476.
- β 33.0 33.1 33.2 Visfeldt J, Andersson M (January 1995). “Pathoanatomical aspects of malignant haematological disorders among Danish patients exposed to thorium dioxide”. APMIS. 103 (1): 29β36. PMIDΒ 7695889.
- β 34.0 34.1 34.2 Brandt L, Emanuelsson H, Mitelman F, Stenstam M, SΓΆderstrΓΆm N (1977). “Pronounced deficiency in T-cells and lymphocyte chromosomal aberrations in a patient with sarcoidosis, myelofibrosis and acute leukaemia following thorotrast angiography”. Acta Med Scand. 201 (5): 487β9. PMIDΒ 302634.
- β 35.0 35.1 Arnold AG, Oelbaum MH (February 1980). “Thorotrast administration followed by myelofibrosis”. Postgrad Med J. 56 (652): 124β7. PMCΒ 2425512. PMIDΒ 7393792.
- β 36.0 36.1 Jennings RC, Priestley SE (December 1978). “Haemangioendothelioma (Kupffer cell angiosarcoma), myelofibrosis, splenic atrophy, and myeloma paraproteinaemia after parenteral thorotrast administration”. J. Clin. Pathol. 31 (12): 1125β32. PMCΒ 1145517. PMIDΒ 748384.
- β 37.0 37.1 McKenney SA, Fehir KM (October 1986). “Myelofibrosis following treatment with a nitrosourea for malignant glioma”. Cancer. 58 (7): 1426β7. PMIDΒ 3742462.
- β 38.0 38.1 Lim DJ, Oh EJ, Park CW, Kwon HS, Hong EJ, Yoon KH, Kang MI, Cha BY, Lee KW, Son HY, Kang SK (December 2007). “Pancytopenia and secondary myelofibrosis could be induced by primary hyperparathyroidism”. Int J Lab Hematol. 29 (6): 464β8. doi:10.1111/j.1365-2257.2006.00877.x. PMIDΒ 17988303.
- β 39.0 39.1 39.2 39.3 39.4 39.5 39.6 39.7 39.8 Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J, Singh R, Mehrotra M, Routbort MJ, Luthra M, Manshouri T, Santos FP, Kantarjian H, Verstovsek S (August 2015). “Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib”. Blood. 126 (6): 790β7. doi:10.1182/blood-2015-03-633404. PMCΒ 4528066. PMIDΒ 26124496.
- β Hiwada K, Sera Y, Nishimura M (July 1970). “[Autopsy case of secondary myelofibrosis due to bone marrow metastasis of stomach cancer]”. Iryo (in Japanese). 24 (7): 585β90. PMIDΒ 5458299.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]
